‘We need to relook at our IPR laws’
The Modi Government should focus on three As of healthcare delivery viz. Availability, Affordability and Access. To achieve this,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
‘Create an ecosystem that encourages innovative R&D in the pharma space’
We believe that a decisive mandate for the Modi Government is definitely a welcome outcome. A decisive mandate will create a…
‘Government should work as a facilitator and not as a regulator’
The Modi governmen should encourage Indian pharma industry to have the slogan "Discover in India" and not "Made in India "…
‘Bulk drug industry needs special financial package’
Indian bulk drug industry has been losing to Chinese competition and our dependence on Chinese APIs has been increasing. It is…
‘Prioritise IP rights, to create a constant cycle of innovation that will help sustain India’s…
PhRMA and its member companies are eager to work with the new government to strengthen the biopharma industry’s relationship with…
‘Main focus should be on developing a mass-based health insurance system’
Five years ago, in the same publication, I wrote about what are healthcare matters and what should be the priorities of the then…
‘Set up fast track courts to address IPR disputes’
The Organisation of Pharmaceutical Producers in India (OPPI), much like the rest of industry has high expectations of the new…
‘New government should get its regulatory role restored’
Over the last three years medical research in India has been brought to standstill. Clinical trials are essential for affordable…
Glenmark opens antibody manufacturing facility in Switzerland
The manufacturing facility supplements the research and development capabilities and will facilitate production of clinical grade…
Indian consumers lack awareness on medical devices: AdvaMed
60 per cent of respondents think that medical devices are the same as pharmaceuticals